GDRX
GoodRxANasdaq / Health Care Equipment & Services
Last Price
At close
2026-07-17
Current thesis
The cleanest bull read is that Q1 validated management’s newer growth legs: Pharma Direct grew 82%, subscription revenue grew 16%, full-year revenue guidance was raised to $765-$785 million, and adjusted EBITDA guidance was kept above $235 million [#SEC-8K-2026-05-06].
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.3.
What can break
Adjusted EBITDA margin fell to 30.0% from 34.4% and net income fell to $1.2 million from $11.1 million, so growth is not yet translating into cleaner profitability [#SEC-8K-2026-05-06].
Momentum
63
Value
70
Sentiment
51
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.10 · Bull $3.60 · Bear $2.20
Data freshness
Prices
As of 2026-07-17
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-17 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-01 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-17
Investment thesis
As of 2026-07-17
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $3.18
Why
Momentum63 · Δ7d +4.1
Value70 · Δ7d -0.3
Sentiment51 · Δ7d -6.3
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
63
26% active weight
Current posture
7d trendSoftening
Δ7d
+4.1
Δ21d
-16.0
Value
70
39% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
-0.1
Sentiment
51
34% active weight
Current posture
7d trendSoftening
Δ7d
-6.3
Δ21d
-2.3
Why this grade
Composite grade A. Momentum 62.7 / Value 70.0 / Sentiment 50.6
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$1.06B
Beta
1.50
Shares Out
338.68M
P/E (TTM)
33.0
P/S (TTM)
1.20
P/FCF (TTM)
9.16
Rev YoY
-4.4%
EPS YoY
-88.3%
Gross Margin
+80.9%
Op Margin
+10.4%
Net Debt
$280.99M
Current Ratio
1.47
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology